Has Jeffrey Carson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $30,648 in general payments to Jeffrey Carson, MD across 25 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Carson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Carson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Carson, MD

Internal Medicine · New Brunswick, NJNPI 1174693873

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Cerus Corporation at 44.8% of the total. 2024 is the largest year on record at $21,800, more than ten times the $16 reported in 2019. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,648in general payments, 2019–2025

Across 25 payments — averaging $1225.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Cerus Corporation$14K
Bristol Myers Squibb$9K
E.r. Squibb & Sons, L.L.C.$7K
Acera Surgical, Inc.$132
Therapeuticsmd, Inc.$16

$13,741,516in research payments, 2019–2025

Across 71 payments — averaging $193,542 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$13.5M
Terumo BCT, Inc.$252K
Irhythm Technologies, Inc.$2K

What the payments were for

Consulting fees$14,52547%
Speaking & faculty fees$6,00020%
Travel & lodging$9,30230%
Food & beverage$8213%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Cerus Corporation	8	$13,730
Bristol Myers Squibb	12	$9,444
E.r. Squibb & Sons, L.L.C.	3	$7,326
Acera Surgical, Inc.	1	$132
Therapeuticsmd, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INTERCEPT BLOOD SYSTEM FOR PLATELETS$8,700
INTERCEPT BLOOD SYSTEM FOR CRYOPRECIPITATION$4,800
Restrata Wound Matrix$132

How this compares

$30,648 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey →

Medicare billing

Part B allowed, 2024

$57,929

Medicare patients

138

Services billed

462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	36	$46,340
EliquisApixaban	47	$42,878
MounjaroTirzepatide	20	$30,206
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	13	$2,517
Atorvastatin Calcium	200	$2,132
SynthroidLevothyroxine Sodium	35	$1,922
Sildenafil Citrate	12	$1,697
Rosuvastatin Calcium	100	$1,429
Tamsulosin Hcl	58	$1,180
Ezetimibe	34	$909
Omeprazole	51	$881
Irbesartan	16	$864
Tramadol Hcl	13	$829
Amlodipine Besylate	90	$738
Metoprolol Succinate	42	$725

Paid to pharmacies, not to this prescriber.

Other internal medicine in New Brunswick

Stephen MarcellaNew Brunswick$331K
Steven PeskinNew Brunswick$99K
James CoromilasNew Brunswick$32K
David KountzNew Brunswick$23K
David ShulkinMorristown$1.7M
Howard UdermanLakewood$955K
Darshi SunderamEast Orange$530K
Annika DrongeEmerson$401K
Viju VijaysadanKinnelon$325K
Mark MonaneWoodcliff Lake$268K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →